West Pharmaceutical Services Inc (WST): analysis and signal as of September 3, 2026
In short
The published signal is weak, with a vote of 3/3 and a score of 2,0. The main reason lies in a valuation close to 38 times 2026 EPS, which leaves little margin of safety, while the stock has been consolidating below its 50-session moving average since the July peak.
- Current signal
- weak (vote 3/3)
- Deterministic score
- +2.0 → signal expected by the scale : moderate (September 10, 2026)
- Layers
- fundamentals : positive, price : positive, risks : neutral
Triggered rules
| Rule | Weight |
|---|---|
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| penalizes a PEG above 2, the anticipated growth is overpaid (overvalued fast grower) | -1.5 |
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
| moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger | +0.5 |
Thesis
The quality of the business model is real, with a broad competitive advantage in high-end injectable packaging, a high ROIC and growth driven by GLP-1 injectors. The HVP segment is growing at +18 % and adjusted EPS at +29 % year on year, with raised 2026 guidance. However, the valuation, around 38 times 2026 EPS, leaves little margin of safety, while the stock has been consolidating below its 50-session moving average since the July peak. A neutral macroeconomic regime favors defensive healthcare stocks, which supports the signal without lifting the reservation linked to the valuation.
Bull case
The group holds a dominant and nearly irreplaceable position in critical injection components, with 49 % of revenue generated in the HVP segment, which is growing at +18 %. The acceleration of GLP-1s fuels demand. Guidance for 2026 was raised on 23/07/2026, with organic growth of 10 to 11 % and expected EPS between 8,85 and 9,05 USD. The company also repurchased 454 M USD of shares in the first half.
Bear case
The price of 342,63 USD stands +33 % away from the internal share repurchase average price of 258 USD. The forward PER is close to 38 times, with no verified peer multiple for cross-checking. The first quarter of 2026 reveals an accounting divergence, with sales up +21 % against operating cash flow down 30 %. A class action for securities fraud covering 2023-2024 retains an unconfirmed status. Finally, the concentration of the narrative on GLP-1s is flagged by the press as contradicting earlier data.
Scenarios
The bullish scenario, with a probability of 25 %, corresponds to a recovery of the annual high reached on 22/07/2026. The central scenario, with a probability of 50 %, describes a consolidation below the 50-session moving average until the third-quarter results. The bearish scenario, with a probability of 25 %, assumes a breakdown of the 200-session moving average on a closing basis, which would invalidate the thesis.
Risks
The main risk lies in the valuation, around 38 times 2026 EPS, which leaves little room for operational disappointment. The accounting divergence of the first quarter of 2026, with operating cash flow down 30 % despite sales up +21 %, raises questions about the quality of growth. The class action for securities fraud covering 2023-2024, of unconfirmed status, is litigation to monitor. The dependence on the GLP-1 narrative, judged by the press to contradict earlier data, exposes the stock to a correction of the multiple. On the technical side, a breakdown of the 200-session moving average on a closing basis would invalidate the thesis.
Market positioning (short sellers)
- Short interest / shares outstanding
- 3.04 %
- Days to cover
- 4.11
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| T3 2026 results and FY26 GLP-1 contracts guidance | |
| Annual Morgan Stanley Healthcare conference |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| weak (3/3) | No change. The price of 02/09/2026 (342,63 USD, +1,18 %) is later than the verdict of 01/09, but it crosses no decision threshold and the 50-session moving average has not been reclaimed. The deterministic score remains at +2,00 with the same rules triggered. Layers marked « périmé possible » or missing data do not constitute new facts. The verdict of 01/09 is therefore maintained. This is an informational analysis and not personalized advice. | |
| weak (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What signal does the analysis publish on West Pharmaceutical Services?
The signal is weak, for a vote of 3/3 and a score of 2,0. The fundamentals are improving, driven by GLP-1 injectors, an HVP segment at +18 % and raised 2026 guidance. But the valuation around 38 times 2026 EPS leaves little margin of safety, and the stock has been consolidating below its 50-session moving average since the July peak. The neutral macroeconomic regime supports defensive healthcare without lifting this reservation.
Why does the valuation pose a problem despite the growth?
The stock trades at 342,63 USD, which is +33 % above the internal share repurchase average price of 258 USD, and its forward PER is close to 38 times, with no verified peer multiple for cross-checking. This level demands flawless execution. Yet the first quarter of 2026 shows sales up +21 % against operating cash flow down 30 %, an accounting divergence that weakens the reading of the results.
What role do GLP-1s play in the group's results?
The HVP segment, dedicated to high-end injectors, accounts for 49 % of revenue and is growing at +18 %. Adjusted EPS gains +29 % year on year. Guidance for 2026 was raised on 23/07/2026, with organic growth of 10 to 11 % expected and EPS of 8,85 to 9,05 USD. The press notes, however, a narrative concentrated on GLP-1s, contradicting earlier data.
What litigation or gray areas weigh on the case?
A class action for securities fraud covering fiscal years 2023-2024 is ongoing, with an unconfirmed status to date. This litigation comes on top of the accounting divergence of the first quarter of 2026 and the concentration of the narrative on GLP-1s. These elements fuel the caution of the analysis, despite a vote of 3/3 and a score of 2,0.
What would invalidate the thesis?
In technical terms, a breakdown of the 200-session moving average on a closing basis would invalidate the thesis. The stock is currently consolidating below its 50-session moving average since the July peak. The valuation around 38 times 2026 EPS is the other point of fragility, as it leaves little margin of safety in the event of operational disappointment or a loss of momentum in the GLP-1 narrative.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 10-Q (SEC · 10-Q)
- — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; 7.01 Reg… (SEC · 8-K)
- — 1.05 Material Cybersecurity Incidents; 9.01 Financial Statements and Exhibits (SEC · 8-K/A)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 3, 2026; this page was completed on September 3, 2026 at 22:33 (UTC).
- Interests: no position in the stock analysed (WST) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: AbbVie, Inc. (ABBV)
- All analysed stocks
- Public methodology